Signals, Powered By EquityPandit
Strides Shasun has got the US health regulator’s approval for marketing Dutasteride capsules that are used in the treatment of enlarged prostate gland in the American market.
Strides Shasun said in a regulatory filing that the company has received the approval from the US Food and Drug Administration (USFDA) to market Dutasteride capsules in the strength of 0.5 mg.
It further said that “the product has gone off patent on November 20 and Strides Shasun is amongst the first wave of generic players to receive this approval”.
